Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Friedemann Schad MD"'
Publikováno v:
Integrative Cancer Therapies, Vol 19 (2020)
Introduction: Cancer-related fatigue (CRF) occurs frequently in breast cancer patients. The aim of this real-world study was to analyze the longitudinal changes of CRF in breast cancer patients receiving an integrative medicine program, which include
Externí odkaz:
https://doaj.org/article/41d610addce3479eb92992bdc0cff4ac
Autor:
Anja Thronicke PhD, Burkhard Matthes MD, Philipp von Trott MD, Friedemann Schad MD, Christian Grah MD
Publikováno v:
Integrative Cancer Therapies, Vol 19 (2020)
Background: Recent data suggest a beneficial effect of add-on treatment with Viscum album L (VA) on the survival in cancer patients. The objective of this study was to compare the impact of standard oncological therapy plus add-on VA treatment (S+VA)
Externí odkaz:
https://doaj.org/article/1d868b50b2204abda1ee381cd7a2df49
Autor:
Shiao Li Oei PhD, Anja Thronicke PhD, Matthias Kröz MD, Philipp von Trott MD, Friedemann Schad MD, Harald Matthes MD
Publikováno v:
Integrative Cancer Therapies, Vol 19 (2020)
Introduction: Viscum album L extracts (VA) are frequently used in integrative oncology. Aim of this study was to evaluate the impact of add-on VA applications on various patient-reported outcome measures. Methods: A longitudinal real-world study was
Externí odkaz:
https://doaj.org/article/bcb7e9ec0e174bf1b492e20ed6969673
Autor:
Shiao Li Oei PhD, Anja Thronicke PhD, Matthias Kröz MD, Harald Matthes MD, Friedemann Schad MD
Publikováno v:
Integrative Cancer Therapies, Vol 18 (2019)
Background: Viscum album L (VA, mistletoe) extracts are commonly used in integrative oncology. Here the clinical safety profile of additional VA-treatments to standard care in cancer patients with preexisting autoimmune diseases was analyzed. Methods
Externí odkaz:
https://doaj.org/article/8f18bf0f0f304d3ea419bfe0eb278c12
Autor:
Friedemann Schad MD, Jan Axtner PhD, Matthias Kröz MD, Harald Matthes MD, Megan L. Steele PhD
Publikováno v:
Integrative Cancer Therapies, Vol 17 (2018)
Combination strategies involving chemotherapy and monoclonal antibodies (mAb) are commonly used in attempts to produce better clinical outcomes. This practice has led to new and ongoing toxicities that may lead to reductions in dose or noncompliance,
Externí odkaz:
https://doaj.org/article/ae1ca2056c8f4a5382975c2228f2c29d